Citations 3
Reply to “Proper tumor classification and growth rate are key elements when considering indications and results of radiotherapy for head and neck paragangliomas”
Lassen–Ramshad, Yasmin , Özyar, Enis , Alanyalı, Senem , Poortmans, Philip , Houtte, Paul Van , Sohawon, Schoeb, Esassolak, Mustafa , Krengli, Marco , Miller, Robert C. , Demiroz, C. , Akyürek, Serap , Aggerholm‐Pedersen, Ninna , Villà, S. , Thariat, Juliette
Head & Neck | May 6, 2019 | Volume: 41 | Issue: 8 | Pages: 2837-2838
Paraganglioma of the head and neck region, treated with radiation therapy, a Rare Cancer Network study
Lassen–Ramshad, Yasmin , Özyar, Enis , Alanyalı, Senem , Poortmans, Philip , Houtte, Paul Van , Sohawon, Schoeb, Esassolak, Mustafa , Krengli, Marco , Miller, Robert C. , Demiroz, C. , Akyürek, Serap , Aggerholm‐Pedersen, Ninna , Villà, S. , Thariat, Juliette
Head & Neck | January 11, 2019 | Volume: 41 | Issue: 6 | Pages: 1770-1776
Abstract Background Paraganglioma of the head and neck (HNPGL) are rare often benign tumors. Surgery and radiation therapy (RT) are the main treatment choices. We present an analysis of outcome and toxicity after RT from 13 institutions of the Rare Cancer Network. Methods Data were collected using a questionnaire concerning patients' characteristics, treatment, and outcome. A total of 81 patients with 82 HNPGL were analyzed. Results The median follow‐up was 48 months (1‐456). Sixty‐two lesions were treated with conventional RT and 20 lesions with stereotactic RT. Local control (LC) was achieved in 69 out of 77 lesions. Late toxicity occurred in 17 patients. Patients treated with stereotactic RT experienced neither disease progression nor late toxicity. Four patients with a follow‐up longer than 20 years experienced disease progression. Conclusion RT for HNPGL offered good local control with acceptable toxicity. Stereotactic RT might offer better results. Long‐term follow‐up is required.
The Rare Cancer Network: Ongoing Studies and Future Strategy
Özşahin, Mahmut , Mirimanoff, René-Olivier, Thariat, Juliette , Sun, Xu , Atalar, Banu , Lassen–Ramshad, Yasmin , Uğurluer, Gamze , Hallemeier, Christopher L. , Houtte, Paul Van , Krengli, Marco , Zhang, Lan Jun, Funk, Ryan K., Rooney, Jessica, Miller, Robert C. , Hallemeier, Christopher, Chang, Kenneth , Funk, Ryan, Mirimanoff, R.O., Krishnan, Sunil , Hallemeier, Christopher Leigh , Chang, Kenneth Tou En , Thariat, Juliette
Rare Tumors | November 7, 2014 | Volume: 6 | Issue: 3 | Pages: 91-94
The Rare Cancer Network (RCN) was formed in the early 1990's to create a global network that could pool knowledge and resources in the studies of rare malignancies whose infrequency prevented both their study with prospective clinical trials. To date, the RCN has initiated 74 studies resulting in 46 peer reviewed publications. The First International Symposium of the Rare Cancer Network took place in Nice in March of 2014. Status updates and proposals for new studies were heard for fifteen topics. Ongoing studies continue for cardiac sarcomas, thyroid cancers, glomus tumors, and adult medulloblastomas. New proposals were presented at the symposium for primary hepatic lymphoma, solitary fibrous tumors, Rosai-Dorfman disease, tumors of the ampulla of Vater, salivary gland tumors, anorectal melanoma, midline nuclear protein in testes carcinoma, pulmonary lymphoepithelioma-like carcinoma, adenoid cystic carcinoma of the trachea, osteosarcomas of the mandible, and extra-cranial hemangiopericytoma. This manuscript presents the abstracts of those proposals and updates on ongoing studies, as well a brief summary of the vision and future of the RCN.